Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flurbiprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.97 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.97 |
| ▸ | AKR1C3 | P42330 | 11/20 | 0.97 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | FABP2 | P12104 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.97 |
| ▸ | HTR2C | P28335 | 1/20 | 0.97 |
| ▸ | DRD3 | P35462 | 1/20 | 0.97 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.97 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flurbiprofen SCHEMBL5176494 | 0.98 | AKR1C3 (0.94) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL2472737 | 0.98 | AKR1C3 (0.94) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Tarenflurbil SCHEMBL29350102 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Tarenflurbil SCHEMBL26131 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8754978 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL10029029 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8754830 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8755275 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Esflurbiprofen SCHEMBL505817 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL2248 | 0.98 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1916 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| CN-120037177-A | Flurbiprofen emulsion gel external-use pharmaceutical composition and preparation method and application thereof | 北京弘德信医药科技有限公司 | 2025-05-27 | — | — | CN | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| CN-115992121-B | Polypeptide for relieving or inhibiting ocular neovascularization and application thereof | 厦门大学 | 2025-03-04 | — | — | CN | claimed |
| CN-115932135-B | Analysis method of related substances in flurbiprofen sodium gel | 湖南九典制药股份有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-118717652-A | Use of gel comprising flurbiprofen sodium | 湖南九典制药股份有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-118615241-A | Flurbiprofen salt solution and application thereof in anti-inflammatory and analgesic field | 吉林化工学院 | 2024-09-10 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240074944-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2024-03-07 | — | — | US | claimed |
| EP-1651184-A1 | FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING PHARMACEUTICALLY ACTIVE AGENTS | Warner-Lambert Company LLC (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1635796-A1 | FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING SUCRALOSE AS A SWEETENER | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | claimed |
| CN-1750809-A | Fast dissolving orally consumable films containing pharmaceutically active agents | WARNER LAMBERT CO (US) | 2006-03-22 | — | — | CN | claimed |
| EP-1622595-A1 | FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING A MODIFIED STARCH FOR IMPROVED HEAT AND MOISTURE RESISTANCE | Warner-Lambert Company LLC (US) | 2006-02-08 | — | — | EP | claimed |
| US-20040247648-A1 | Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance | MCNEIL-PPC, INC | 2004-12-09 | — | — | US | claimed |
| WO-2004096174-A1 | FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING PHARMACEUTICALLY ACTIVE AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004096192-A1 | FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING A SUCRALOSE AS A SWEETENER | WARNER-LAMBERT COMPANY LLC (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004096193-A1 | FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING A MODIFIED STARCH FOR IMPROVED HEAT AND MOISTURE RESISTANCE | WARNER-LAMBERT COMPANY LLC (US) | 2004-11-11 | — | — | WO | claimed |
| US-20030211136-A1 | Fast dissolving orally consumable films containing a sweetener | MCNEIL-PPC, INC | 2003-11-13 | — | — | US | claimed |
| WO-1994015597-A1 | OPHTHALMIC COMPOSITIONS COMPRISING BENZYLLAURYLDIMETHYLAMMONIUM CHLORIDE | ALLERGAN, INC. (US) | 1994-07-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | PTGS1 2336/4885PTGS2 3239/4885AKR1C3 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.